EUVIMEDEUVIMED entdecken
Open Access

FDA Adverse Event Reporting System ( FAERS ) Essentials: A Guide to Understanding, Applying, and Interpreting Adverse Event Data Reported to FAERS

Emeri Potter iD, Melissa Reyes iD, Jennifer Naples iD, Gerald Dal Pan iD

Clinical Pharmacology & Therapeutics · 2025-09 · 118 (3) · 567-582

DOI: 10.1002/cpt.3701 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 19.05.2025. Verfasst von Emeri Potter und 3 weiteren Autor:innen. Beteiligte Einrichtung: Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA. Hauptthemen laut MEDLINE: Adverse Drug Reaction Reporting Systems, Drug-Related Side Effects and Adverse Reactions, Product Surveillance, Postmarketing, United States Food and Drug Administration. Die Arbeit wurde bisher 147-mal zitiert (Crossref) und nennt 124 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural FDA HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The US Food and Drug Administration (FDA) performs safety assessments throughout the life cycle of a drug. Postmarketing safety surveillance promotes the identification of adverse events not known at the time of approval. Adverse event reports, also called individual case safety reports (ICSRs), submitted to FDA, are collected and stored in the FDA Adverse Event Reporting System (FAERS). ICSRs stored in FAERS may be reviewed—along with multiple other data sources—to detect potential safety signals and to perform a thorough evaluation to determine if a causal association exists between a drug and an adverse event. Although FAERS is a powerful tool for drug safety surveillance and assessment, understanding the content, application, and proper interpretation of the data contained in FAERS is necessary to reach scientifically and medically accurate conclusions and contextualize findings. This article aims to highlight considerations and explain fundamental concepts of FAERS to promote accurate analyses and appropriate interpretation of the data available.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adverse Drug Reaction Reporting SystemsDrug-Related Side Effects and Adverse ReactionsProduct Surveillance, PostmarketingUnited States Food and Drug AdministrationHumansUnited States

Autor:innen und Institutionen

  • Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.

ORCID-Profile: Emeri Potter, Melissa Reyes, Jennifer Naples, Gerald Dal Pan

Förderung

  • Intramural FDA HHS

Zitieren

APA

Potter, E., Reyes, M., Naples, J., & Dal Pan, G. (2025). FDA Adverse Event Reporting System ( FAERS ) Essentials: A Guide to Understanding, Applying, and Interpreting Adverse Event Data Reported to FAERS. Clinical Pharmacology & Therapeutics, 118(3), 567-582. https://doi.org/10.1002/cpt.3701

Vancouver

Potter E, Reyes M, Naples J, Dal Pan G. FDA Adverse Event Reporting System ( FAERS ) Essentials: A Guide to Understanding, Applying, and Interpreting Adverse Event Data Reported to FAERS. Clinical Pharmacology & Therapeutics. 2025;118(3):567-582. doi:10.1002/cpt.3701

BibTeX
@article{Potter2025,
  author = {Potter, Emeri and Reyes, Melissa and Naples, Jennifer and Dal Pan, Gerald},
  title = {FDA Adverse Event Reporting System ( FAERS ) Essentials: A Guide to Understanding, Applying, and Interpreting Adverse Event Data Reported to FAERS},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2025},
  volume = {118},
  number = {3},
  pages = {567--582},
  doi = {10.1002/cpt.3701}
}
Kostenlos starten →